Dr. Paz-Ares Discusses the Use of Pemetrexed for NSCLC

Luis Paz-Ares, MD, PhD

Published Online: Friday, June 17, 2011

Print

Email

Luis Paz-Ares, MD, PhD the chair of oncology at Seville University Hospital in Spain discusses the use of pemetrexed in advanced nonsquamous non–small cell lung cancer.

View more videos of Luis Paz-Ares, MD, PhD.

Comment(s)

Your comments are valuable to us. Thank you.

Sorry, you must be logged in and registered to post a comment.

Related Articles

Maintenance Therapy With Bevacizumab/Pemetrexed Appears Superior to Bevacizumab Alone

Maintenance therapy with bevacizumab plus pemetrexed achieved a 4-month benefit in progression-free survival (PFS) versus bevacizumab maintenance therapy alone.

MetMAb Plus Erlotinib Improves Survival for Patients With MET-Positive NSCLC

Add-on therapy with an inhibitor of the MET signaling pathway significantly improved PFS and OS in patients with MET-positive NSCLC confirmed by immunohistochemistry.

New Crizotinib Results Show Positive Outcomes

Crizotinib demonstrated marked antitumor activity among patients with advanced ALK-positive non–small cell lung cancer.

Most Popular Right Now

Telemedicine a Valuable Way to Deliver Healthcare

ASCO: A Focus on Personalized Medicine

The Rising Cost of Cancer Care in the Era of Individualized Therapy: A Q&A With Thomas J. Smith, MD

Dr. Ladenson on Diagnosis of Thyroid Nodules

Photopheresis Process Offers Relief From Lymphoma Lesions: An Interview With Dennis Parenti, MD

Bringing the Oncology Community Together

Dr. Paz-Ares Discusses the Use of Pemetrexed for NSCLC